但这种垄断格局，即将被打破，多款在研新药正从作用机制到给药方式，向Vosoritide发起挑战。Ascendis的TransCon-CNP通过包裹技术延长了药物作用时间，实现了周剂给药，目前正处于FDA审批阶段；而BridgeBio的口服药Infigratinib，则从作用机制到用药体验实现全面突破。
# What you gain
，详情可参考heLLoword翻译官方下载
For others considering using weight-loss drugs and whether there was anything they could do to reduce the risk of developing gallstones, Hewes said: "Losing weight in a slower and a controlled manner is likely to reduce your chances of getting gallstones."
See all 20 tools →
What is this page?